Argus downgraded shares of Gilead Sciences, Inc. (NASDAQ:GILD) from a buy rating to a hold rating in a report issued on Monday morning, MarketBeat.com reports. They currently have $73.77 target price on the biopharmaceutical company’s stock, up from their previous target price of $73.25.
GILD has been the topic of a number of other research reports. BidaskClub downgraded shares of Gilead Sciences from a buy rating to a hold rating in a research note on Wednesday, August 9th. Vetr downgraded shares of Gilead Sciences from a strong-buy rating to a buy rating and set a $82.15 price target on the stock. in a research note on Monday, August 28th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $73.00 to $81.00 and gave the stock a market perform rating in a research note on Wednesday, September 6th. Oppenheimer Holdings, Inc. assumed coverage on shares of Gilead Sciences in a research note on Thursday, October 5th. They set a market perform rating on the stock. Finally, Deutsche Bank AG reiterated a buy rating and set a $81.00 price target (up previously from $79.00) on shares of Gilead Sciences in a research note on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $84.87.
Gilead Sciences (GILD) traded up $0.60 on Monday, reaching $72.41. 7,535,900 shares of the company’s stock were exchanged, compared to its average volume of 9,352,579. Gilead Sciences has a 1 year low of $63.76 and a 1 year high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The firm has a market capitalization of $94,560.00, a P/E ratio of 7.50, a P/E/G ratio of -1.20 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the previous year, the company earned $2.75 earnings per share. The business’s revenue was down 13.2% compared to the same quarter last year. analysts forecast that Gilead Sciences will post 8.53 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/gilead-sciences-inc-gild-downgraded-to-hold-at-argus/1781778.html.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be given a $0.52 dividend. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.87%. Gilead Sciences’s dividend payout ratio is presently 23.66%.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $83.11, for a total value of $6,094,705.63. Following the transaction, the insider now directly owns 2,996,766 shares of the company’s stock, valued at approximately $249,061,222.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 666,819 shares of company stock valued at $52,303,086. Insiders own 1.30% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Seizert Capital Partners LLC boosted its position in Gilead Sciences by 4.6% during the 1st quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock worth $42,964,000 after acquiring an additional 27,547 shares during the last quarter. Investment Centers of America Inc. raised its stake in shares of Gilead Sciences by 7.2% during the 1st quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock worth $1,979,000 after purchasing an additional 1,958 shares in the last quarter. Fagan Associates Inc. raised its stake in shares of Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after purchasing an additional 845 shares in the last quarter. Capital Asset Advisory Services LLC bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $875,000. Finally, First PREMIER Bank raised its stake in shares of Gilead Sciences by 9.0% during the 2nd quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock worth $1,524,000 after purchasing an additional 1,787 shares in the last quarter. 74.62% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.